Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23
Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. The availability of a range of novel, targeted therapies for their treatment, most notably the availability o...
Saved in:
Main Authors: | K. M. Darch, T. L. Holland, L. J. Spelman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/9404505 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The frequency of distribution of the genotypes of the IL4 polymorphism (rs 2243250) in psoriasis and psoriatic arthritis
by: A. A. Barilo, et al.
Published: (2019-02-01) -
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
by: Eleonora Celletti, et al.
Published: (2025-01-01) -
The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis
by: Athanasios Mavropoulos, et al.
Published: (2013-01-01) -
Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report
by: Yixiao Wei, et al.
Published: (2025-01-01) -
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
by: A. Egeberg, et al.
Published: (2022-07-01)